Method of treating lung cancer complicated by hemorrhage
SUBSTANCE: invention relates to medicine, oncology and radiology and consists in carrying out complex treatment by installation of endobronchial reverse valve into bleeding bronchus. At this background performed is external beam radiotherapy (EBRT) TFD 40 Gy, with radiomodifier: 5 fluorouracil - 250 mg, course dose - 4-5 g, or cysplatin - 10 mg, course dose - 120 mg, which are introduced daily, intravenously 30 minutes before the beginning of EBRT session. 14 days after completion of the first stage of EBRT fibrobronchoscopy (FBS) is performed with removal of bronchoblocker, and the second stage of EBRT TFD 30 Gy is performed to total dose for two stages EBRT TFD 70 Gy, with application of the same radiomodifiers in the same mode. 30 days after finishing EBRT FBS is made and is tumour remains in bronchus lumen or there is a suspicion of it, photodynamic preparation is introduced intravenously, and after 4 hours FBS and laser irradiation of tumour are carried out. Control examination of tracheobroncial tree is carried out after 30 days and after 26 months.
EFFECT: method ensures increase of life expectancy and improvement of its quality for patients with non-operable lung cancer complicated by hemorrhage.
The invention relates to medicine, namely to Oncology, and can be used for special treatment of lung cancer complicated by bleeding.
A method of treatment of lung cancer complicated by pulmonary hemorrhage, at the present time is urgent as pulmonary hemorrhage occurred on the background of lung cancer, is an absolute contraindication for carrying out of special treatment, namely chemotherapy and radiation treatment (this greatly aggravates the condition of the patient with lung cancer and is the leading cause of death of the patient from profuse bleeding or asphyxia). From sources not identified a method of treating lung cancer, complicated by bleeding, special methods, such as chemotherapy and radiation treatment.
There is a method of treatment of pulmonary tuberculosis (RF patent No. 2002133917), consisting in the application to stop pulmonary hemorrhage endobronchial valve, which provides prevention of asphyxia and evaperation pneumonia (in the early period pulmonary hemorrhage), and by maintaining the drainage function of the blocked bronchus excludes postobturation pneumonia - this allows you to keep the bronchial obturation up to 6 months. However, it is not used in patients with lung cancer, complicated by bleeding, for the conduct is of chemotherapy and radiation treatment.
The authors offer a highly effective method of treating patients with lung cancer, complicated by bleeding, which consists in carrying out step therapy:
the first step is to stop lung hemorrhage by asking endobronchial valve (bronchomalacia) in the bleeding bronchus;
in the second stage, 2-4 day after establishing bronchomalacia in bleeding bronchus, perform chemotherapy and the first stage remote radiation therapy SOD-40 Gr;
the third stage includes: within 14 days after the end of chemotherapy and the first stage remote radiation therapy is fibrobronchoscopy with the removal of endobronchial valve and revision of the bronchial tree to evaluate the effectiveness of the treatment. Then comes the second stage remote radiation therapy SOD-30 G during chemotherapy, the total dose of remote radiation therapy in two stages - SOD-70 Gr;
the fourth stage - at the end remote radiation therapy SOD-70 Gy in 30 days is fibrobronchoscopy to assess the effectiveness of the treatment and when saving or suspected tumor in the lumen of the bronchus, intravenous photodynamic drug, and after 4 hours the fibrobronchoscopy and laser irradiation of the tumor.
The technical result of the proposed method is to increase the longevity and improve its quality in patients with inoperable form of lung cancer, complicated by bleeding, by conducting effective special treatment in the first days after stopping lung hemorrhage by asking endobronchial valve (bronchomalacia) in the bleeding bronchus (formerly bleeding from the tumor was an absolute contraindication to chemoradiation therapy).
The technical result is achieved by the fact that the authors suggest that the only acceptable method of treatment of patients with lung cancer, complicated by bleeding from the tumor:
the first step is to stop lung hemorrhage by asking endobronchial valve in the bleeding bronchus;
in the second stage amid bronchomotor carry out the survey (2-4 days) for remote radiation therapy to the primary tumor site, regional lymph nodes and perform the 1st step radiotherapy SOD-40 Gy with radiomodifying: chemotherapy - 5 proracer 250 mg, dose rate to 4-5 g, or cisplatin 10 mg, dose rate to 120 mg administered daily intravenously 30 minutes prior to the start of the remote session radiotherapy;
the third stage includes: upon completion of chemotherapy and the first stage remote radiation therapy (2 weeks before the 2nd stage remote radiation therapy), you fibrobronchoscopy with the removal of endobronchial treatment is tion of the valve of the bronchus and revision of the bronchial tree to evaluate the effectiveness of the treatment. Then comes the second stage remote radiation therapy SOD-30 Gy to a total dose of remote radiation therapy in two stages - SOD-70 Gr, amid radiomodifying: chemotherapy - 5 proracer 250 mg, dose rate of 4 g, or cisplatin 10 mg, dose rate to 120 mg administered daily intravenously 30 minutes prior to the start of the remote session radiotherapy;
the fourth stage is the completion of a course of radiation therapy SOD-70 Gy in 30 days is fibrobronchoscopy to assess the effectiveness of the treatment and when saving or suspected tumor in the lumen of the bronchus intravenous photodynamic drug, and after 4 hours the fibrobronchoscopy and laser irradiation of the tumor.
Patient S. 54 years of age, was treated in the thoracic Department.
The diagnosis of Central cancer of the left main bronchus T3N3Mx, recurrent pulmonary hemorrhage 2 severity".
Chest x-ray: left lung is reduced in volume due to hypoventilation lower lobe. At the root node is determined education with irregular contours, deforming the lumen of the proximal bronchus. The mediastinum is displaced to the left. Determined enlarged lymph nodes of all groups mediastinum on both sides.
The fibrobronchoscopy. Proximal bronchus obturated buhr stem infiltration, who goes on an extended midlevel spur, the rear wall of the upper lobe bronchus and the rear semicircle of the left main bronchus, covered in the last 1/3 of the lumen. The proximal border of 4 cm from the crest of Karina. On the surface of the tumor, the walls of the trachea blend of blood clots.
Histological diagnosis of squamous cell carcinoma.
In spite of hemostatic therapy for 9 days, bleeding from the left main bronchus continued. When fibrobronchoscopy in the left main bronchus set endobronchial valve (bronchomotor) No. 14. Pulmonary hemorrhage stopped.
Chest x-ray: left lung in atelectasis.
Control fibrobronchoscopy 2 days - bronchomotor in the left main bronchus, blood traces in the bronchus no.
Computed tomography of the chest: the left lung field is reduced in volume due to atelectasis, in the lumen of the main bronchus synthetic obturator. The right lung field normal size, the density of the lung tissue normal lung pattern is not modified, visible bronchi passable, the walls of their slightly thickened. Determined enlarged paratracheal nodes on the right. Conclusion: Central cancer of the left lung, metastases in the lymph nodes of the mediastinum.
The Council of radiologists - recommended course distance the ion radiotherapy with radiomodifying - 5 fluorouracil 250 mg, dose rate to 4-5 grams a day intravenously 30 minutes before the start of the remote session of radiotherapy. Started a course of chemotherapy after 4 days from the moment of bronchomalacia. At the first stage of treatment stop lung hemorrhage by asking endobronchial valve (bronchomalacia) in the bleeding bronchus, in the second stage of treatment the patient received: remote radiation therapy - SOD - 40 Gr and intravenous 5 fu 250 mg, dose rate - 5 year
After 14 days upon completion of the 1st stage remote radiation therapy conducted fibrobronchoscopy, during which bronchomotor removed from the bronchus. During inspection of the bronchial tree data no bleeding.
Thus, the proposed method for the treatment of lung cancer complicated by bleeding, is the gradual realization of complex treatment. To stop the bleeding bronchus is setting bronchomalacia in bleeding bronchus, conducting remote radiation therapy radical programme - SOD - 70 Gy with one radiomodifying is 5 fluorouracil or cisplatin. The first step is to stop lung hemorrhage by asking endobronchial valve in the bleeding bronchus. In the second stage of treatment amid bronchomotor held remote radiation therapy day the SOD 40 Gr amid radiomodifying: this chemotherapy with 5 fluorouracil 250 mg, dose rate to 5 g daily intravenously 30 minutes before the start of the remote session of radiotherapy. In the third stage after 14 days upon completion of the 1st stage remote radiation therapy is fibrobronchoscopy with the removal of bronchomotor of bronchus and revision of the bronchial tree to evaluate the effectiveness of the treatment and a second stage remote radiation therapy SOD-30 Gy to a total dose of remote radiation therapy in two stages - SOD-70 Gr amid radiomodifying - 5 fluorouracil 250 mg, dose rate to 4 g daily intravenously 30 minutes before the start of the remote session radiation therapy.
The fourth stage - fibrobronchoscopy 30 days upon completion of the remote radiation therapy: in the proximal bronchus is determined by the infiltration of the mucous membrane, passing to the rear wall of the upper lobe bronchus and the rear semicircle of the left main bronchus, the latter has a tumor of 0.3×0.2 cm, was introduced intravenously photodynamic Photosens 0,2%-50,0, and after 4 hours the fibrobronchoscopy and laser irradiation of the tumor from 100-300 j/cm2.
Control examination after 30 days. The fibrobronchoscopy: during the inspection of the mucosa of the tracheobronchial tree pathology it is not revealed.
The last survey in 26 months. State Boling is satisfactory, no complaints. Performed fibrobronchoscopy, in which the pathology in the mucosa of the tracheobronchial tree not found.
The claimed method of treatment with high efficiency to provide specialized care to patients with lung cancer, complicated by bleeding, which previously refused to specialized treatment, and can be used in specialized Oncology institutions engaged in comprehensive treatment of patients with lung cancer.
A method of treating patients with lung cancer, complicated by bleeding, which consists in carrying out a comprehensive treatment by asking endobronchial valve in the bleeding bronchus, against which perform remote radiation therapy SOD - 40 Gy, with radiomodifying - 5 fluorouracil 250 mg, dose rate to 4-5 g, or cisplatin 10 mg, dose rate of 120 mg, which is administered daily, intravenously 30 min before the start of the remote session of radiotherapy, at the end of the 1st stage remote radiation therapy within 14 days perform fibrobronchoscopy, during which bronchomotor removed from the bronchus, and carry out the second stage remote radiation therapy SOD - 30 Gy to a total dose of two stage remote radiation therapy SOD - 70 Gy, with radiomodifying - 5 - fluorouracil 250 mg, dose rate of 4 g, or cisplatin 10 mg, to ROWA dose of 120 mg, introducing daily, intravenously 30 min before the start of the remote session radiation therapy within 30 days after the remote radiotherapy perform fibrobronchoscopy and when saving or suspected tumor in the lumen of the bronchus intravenous photodynamic drug, and after 4 h the fibrobronchoscopy and laser irradiation of the tumor, visual inspection of the tracheobronchial tree are performed every 30 days and 26 months.
SUBSTANCE: invention relates to tetracyclic antibiotic anthraquinone derivatives having anticancer activity.
EFFECT: tetracyclic antibiotic anthraquinone derivatives described in the present invention have the same or higher activity than current medicinal agents such as doxorubicin, daunorubicin or similar, in a cellular level, and at the same time have better tolerance than doxorubicin and daunorubicin for animal organism.
15 cl, 54 ex, 3 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention describes poly(ADP-riboso)polymerase inhibitors of formula (Ik) its pharmaceutically acceptable salt wherein R101, R104 and R105 represent H; R102 represents R11 wherein R11 is specified from pyrrolidinyl, oxazolyl, imidazolidinyl, isothiazolidinyl, piperidinyl, piperazinyl and azepanyl with R102 being substituted by one or two (O) substitutes; R103 represents fluorine, besides, a pharmaceutical composition on the basis of said compounds showing poly(ADP-riboso)polymerase (PARP) inhibitory activity, a method of treating cancer and a method of reducing tumour volume in a mammal.
EFFECT: there are produced and described new compounds which show poly(ADP-riboso)polymerase (PARP) inhibitory activity.
9 cl, 491 ex, 2 tbl
SUBSTANCE: invention concerns medicine, oncology, and is applicable for photodynamic therapy of malignant growths. That is ensured by photodynamic therapy. For this purpose, a photosensitiser is introduced in suppositories through rectum. The photosensitiser is presented by mixed chlorine derivatives and spirulina platensis with added excipient for suppositories. The suppository ingredients are taken in the following proportions, wt %: chlorine derivatives -0.1-0.4; spirulina platensis -3-4.5; excipient - 95.1-96.9. The new grown is exposed to light at wave length corresponding to a maximum absorption of chlorine derivatives.
EFFECT: method enables higher clinical effectiveness, eliminated disadvantage of the invasive introduction.
7 cl; 2 ex
SUBSTANCE: what is presented is a group of inventions which refers to medicine, namely oncology. The group of inventions involves a recovered PDGFRcc-specific human antibody or an antibody fragment, a recovered polynucleotide, an expression vector, a recombinant cell, an antibody or an antibody fragment produced by recombinant cell culture, and also the use of these antibodies or their fragments for tumour growth inhibition in leiomyosarcoma and glioblastoma.
EFFECT: invention enables successful treatment of leiomyosarcoma and glioblastoma ensured by the use of the antibodies or their fragments which bind with human PDGFRoc and neutralise activation of the receptors involved in tumour angiogenesis growth.
10 cl, 20 dwg, 8 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the use of potassium osmate salt K2[OsO2(OH)4] with isotope 187Os as a anticancer agent.
EFFECT: salt shows high anticancer activity in system in vivo with no undesired side effects.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry, medicine, biotechnology, and concerns a method for producing dextrane phosphate hydrogels which can find application in preparing prolonged preparations for treating oncological diseases, infectious diseases, immune disorders. The declared invention describes the method for producing polysaccharide phosphate hydrogels, involving processing of an initial polysaccharide in mixed orthophosphoric acid and phosphorus oxide (V) in an organic solvent medium in the presence of trialkylphosphate at temperature 30-70°C that is followed by washing of the prepared products, drying and processing in an aqueous solution of a mineral compound with the etherification process of dextrane conducted in a non-polar organic solvent medium of the low boiling point specified in hydrocarbons and their derivatives and processing of the prepared product in 0.005-0.5 M aqueous solutions of sodium carbonate, or sodium hydrocarbonate, or sodium hydroxide, or their mixtures to the value pH 3.0-8.0 to be set down in ethanol and dried at temperature 20-50°C.
EFFECT: invention allows producing dextrane phosphate characterised by high pharmacological activity indices.
9 ex, 4 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: there are offered: using synergistically effective amounts of compounds of formula I (oridonin), II (particularly vogonin) and IV (particularly, 2,4,4'-trihydroxychalcone) for preparing a drug preparation for treating neoplasia resistant to a therapeutic agent, specified in a group consisting of prostate cancer, breast cancer, endometrial cancer, colon cancer, lung cancer, bladder cancer, testicular cancer, ovarian cancer, thyroid cancer and bone cancer; an appropriate composition and a method of treating. What is shown is: strong synergetic action of the ingredients of the composition according to the present invention. It makes them applicable in relatively low amounts to treating stage IV cancer or recurrent cancer which can be characterised by developed resistance to conventional chemotherapeutic agents.
EFFECT: compounds and methods according to the invention are especially applicable for treating human taxol-resistant cancers, particularly uterus neck cancer and breast cancer.
20 cl, 3 tbl
SUBSTANCE: compound contains IL-15 indirectly bound by covalent links with a polypeptide containing a sushi domain of an extra-cellular region of the alpha IL-15R subunit.
EFFECT: invention allows inducing and stimulating activation and proliferation of said cells, and effectively treating the conditions and diseases which requires higher activity of IL-15.
44 cl, 42 dwg, 4 tbl, 1 ex
SUBSTANCE: invention relates to stable metastin derivatives, having excellent biological activity. The disclosed metastin derivatives improve stability, gelation tendency is reduced, pharmacokinetics are also improved, and an excellent cancer metastasis suppressing activity or a cancer growth suppressing activity is exhibited.
EFFECT: metastin derivatives of the present invention also have a gonadotropic hormone secretion suppressing activity and sex hormone secretion suppressing activity.
5 cl, 4 tbl, 18 ex
SUBSTANCE: invention relates to a diacetate of racemic 18-ethyl-gona-1,3,5(10),8(9)-tetraene-3,17β-diol, having anti-implantation and antioxidant activity with low uterotropic action. Presence of antioxidant activity in said steroid is essential since compounds with such action can be agents for preventing oestrogen-dependent breast cancer.
EFFECT: compounds exhibit anti-implantation and antioxidant activity with low uterotropic action, which is an advantage over agents used in practice.
1 cl, 1 ex, 4 tbl
SUBSTANCE: invention refers to medicine, concerns treating cancer. The tumour is exposed to gamma photon with a radiation source cobalt-60 at gamma photon radiation energy 1.25 MeV. A patient takes herbal infusion 400-500 ml 30-40 min before the radiation therapy session: Alexandrian laurel leaves, burdock leaves, alder blossom, dill seeds, celandine herb, nettle herb and sage herb in equal portions. The plants are pre-dried in the shade to humidity 14-16 %, then each is taken in the amount of 100 g, mixed and powdered. The herbal powder 40-50 g is filled with boiling water 500-600 ml, boiled for 3 min, and settled for 2-3 hours. Between the radiation therapy sessions, the patient takes the infusion 200-250 ml twice a day, and after the termination of the therapeutic course, the infusion 200-250 ml is prescribed once a day.
EFFECT: method provides clinical effectiveness ensured by prevented metastases formation.
SUBSTANCE: invention refers to medicine, namely oncology, and can be used for treating cervical cancer. That is ensured by radiation teletherapy and brachytherapy. Each brachytherapy session is preceded by bringing the Hydrogel Coletex-M Tissue 3-5 ml to the tumour before 12-18 hours. Before gel contact, the Coletex-M Tissue is introduced. Further,1-1,5 hours prior to the brachytherapy session, the textile tissue is removed, and Hydrogel Coletex-ADL Tissue 4-6 ml is brought to the tumour. Preliminary, the Hydrogel Coletex-ADL Tissue is added with lidocaine to achieve the gel concentration 4-6%.
EFFECT: method provides reduced total toxicity and drug load ensured by the required concentration of metronidazole maintained in the tumour before the radiation session, and also analgesia without using narcotic preparations, optimised time and geometry of centring introduction that allows intensifying the damage exposure on the tumour.
SUBSTANCE: invention refers to medical equipment, namely to radiation therapeutic apparatuses. An apparatus comprises an X-ray source with an electronic gun, a target and a electrode potential source of an electronic gun cathode, a resonator arranged along an electron ray and connected to a microwave signal source allowing frequency tuning, a detector of passed pathological radiation material, a frequency recorder. A conductor is introduced to couple a resonator and said target. The resonator is toroidal and has a gap to pass the electron ray, while a distance of the resonator gap and the target is specified provided 1.3>UINπfd/v0|Up|>1.1 wherein UIN is a microwave signal amplitude in the resonator gap, f is a microwave signal frequency, d is a distance of the gap and the target, v0 is an electron flow, Up is a cathode potential of the electronic gun cathode with respect to the resonator.
EFFECT: use of the apparatus provides more complete elimination of pathology of the radiated biological material.
2 cl, 4 dwg, 1 tbl
SUBSTANCE: invention refers to medicine, namely oncology, and is applicable for treating rectal cancer with synchronous remote metastases. That is ensured by radiation therapy together with radio modifiers and combined with chemotherapy followed by radical resection of a primary tumour and remote metastases. The radio modifiers are presented by the intrarectal introduction of metronidazole as a part of a composite mixture containing sodium alginate and 2% dimethylsulphoxide, and also local microwave hyperthermia. The chemotherapy is presented by a two-day intensive course of chemotherapy FOLFOX6 involving high doses of platinum and 5-fluorouracil in the form of the 48-hour infusion.
EFFECT: method allows reducing total length of treatment, enabling a complete course of effective preoperative radiation chemotherapy with minimum toxicity in a relatively short time, performing earlier sphincter-preserving operations with well-timed resection of the primary tumour, regional and remote metastases ensured by implementing mechanisms, chemosensitisation and synergic effect of said radio sensitising agents.
SUBSTANCE: invention refers to medicine, oncology, particularly, by methods of conservative treatment of the patients suffering early breast cancer. It involves 3D conformal radio therapy (CRT) covering a removed tumour bed including 2 cm of surrounding healthy tissues; single basic dose is 2.5 Gy twice a day at a fraction interval of 6 hours, to total basic dose 40 Gy. The irradiation is performed within 8 days.
EFFECT: method provides an adequate irradiation of the removed tumour bed minimally damaging the surrounding healthy tissues, preventing recurrences, reduced risk of developing radiation injury, excellent/good cosmetic effect.
SUBSTANCE: invention refers to medicine, namely oncology, and aims at combination treatment of locally advanced rectal cancer. It involves radiation therapy with underlying introduction of capecitabine 825 mg/m2 times a day on the radiation days. The treatment is two-staged: the fist stage involves gamma-ray teletherapy in a standard fractionation mode at single basic dose 2.0 Gy for 5 days a week to total basic dose 40.0 Gy. At the second stage, the interval of 14 days is followed by 5 sessions of intracavitary gamma-ray therapy at single basic dose 3.0 Gy to total basic dose 16 isoGy.
EFFECT: method provides higher clinical effectiveness in locally advanced rectal cancer ensured by higher radiation dose directly covering the tumour and reduced radiation dose on healthy organs and tissues.
SUBSTANCE: invention refers to medicine, particularly to oncology, and may be applied in treating locally advanced breast cancer with tumour skin ulceration. That is ensured by CMF chemotherapy, 5-fluorouracil chemotherapy in the form of Koletex-5-fluor tissue applications and radiation therapy. The Koletex-5-fluor tissues are applied on the ulcer centre daily 2-3 times a day and changed every 2 days. The radiation therapy is performed in a mode of average dose fractionation on an area of a breast base and an area of regional lymph outflow. Herewith, 5-7 days before the radiation therapy, the ulcer area and the whole breast are coated with a thin layer of the 'Hydrogel Coletex-Phyto Tissue' material 3 times a day. Additionally, the ulcer area is coated with the 'Coletex-Phyto' textile tissues above the hydrogel material. The radiation directly covers the tissue and hydrogel. The ulcer borders are treated with the 'Hydrogel Coletex-Phyto Tissue' material 2-3 times a day for the whole period of radiation. After the termination of the radiation therapy, the ulcer centre is coated with the 'Coletex-Phyto' textile tissues, while the ulcer borders are treated with the 'Hydrogel Coletex-Phyto Tissue' material for 1-2 weeks.
EFFECT: implementing the method provides higher clinical effectiveness ensured by faster healing of tumour ulcers, reduced drug load, lower toxicity and enabled continuous radiation therapy.
SUBSTANCE: group of inventions relates to medicine. A therapeutic system comprises an imaging device, a therapy planning unit, a therapeutic device. The therapy planning unit comprises a therapy prescription unit which calculated the required therapy to be applied in a patient or any other object. The therapy prescription system uses a pathology model and a history of biological values specific for the patient for purposes of optimising the applied therapy.
EFFECT: use of the given group of inventions enables adapting the therapy plan with taking into consideration the biological variations regarding a specific pathology or a patient.
43 cl, 6 dwg
SUBSTANCE: invention refers to medicine, oncology, and can be used for combination treatment of the patients suffering eyelid malignancies. A method involves local radiomodification by peritumoral introduction of Methotrexate 10 mg pre-incubated in autoplasma 10 ml at t=37°C for 30 minutes preceded by subbulbar introduction of diprospan 1 ml. One hour later, the radiomodification is followed by neoadjuvant radiation therapy at depth 0.5 cm by basic dose 20 Gy, and no more than 24 hours after the radiation, a surgical operation is performed.
EFFECT: method provides intensified radicality of the tumour exposure, higher surgical ablasticity, lower risk of cancer dissemination, maximally maintained reparation ability and functions of normal ocular tissues, minimised therapeutic complications, reduced length of treatment.
SUBSTANCE: invention refers to medicine, particularly to oncology, and can be used for the purpose of radiation therapy of locally advanced forms of breast cancer T2-4N1-3M0-1 with unfavourable prognostics. A postoperative cicatrix is exposed to fast neutron 6.3 MeV within 3 sessions from two or three fields of radiation, in single radiation dose - 1.4-1.76 Gy to total isoeffective basic dose - 25-32 Gy.
EFFECT: method provides reducing a number of recurrences and complications.
SUBSTANCE: invention refers to medicine, namely gynaecology, venereology and immunology, and is applicable for local immunocorrection of female infectious-inflammatory urogenital diseases caused by sexually-transmitted microorganisms. For this purpose, with underlying drug-induced therapy, the immunomodulatory therapy is used from first day of therapy by magnetic laser exposure on a uterus neck. The uterus neck is exposed by a gynecologic speculum which is removed after the procedure is completed. The magnetic laser exposure immediately covers a cervical canal. That is ensured by using a low-intensity laser with variable pulse generation. The magnetic field intensity makes 1.25 T. Pulse train frequency per minute is 30. A pulse interval is 100 msec. Length of the exposure is 5 minutes. The therapeutic course is 10 procedures.
EFFECT: method provides higher complex clinical effectiveness ensured by normalising local immunity factors, namely functional activity recovery of neutrophilic granulocytes of the cervical canal, higher concentration of pro-inflammatory cytokines, immunoglobulins A, M, G in the cervical canal.
3 tbl, 3 ex